Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2019

View Archived Issues

JMJD6 predicts poor prognosis in ovarian cancer and can be a new therapeutic target

Evaluation of the effects of atractylenolide I in a new mouse model of cancer cachexia

CRISPR targets fat cells, improves metabolism

Antimalarial kinase inhibitor identified at the University of Glasgow

Soluble RANKL inhibition may prevent tumor metastasis to bone

Discovery of novel R-PTP-sigma inhibitors to promote hematopoietic stem cell regeneration

Preclinical and phase I data presented for SAR-439859

CC-90011 demonstrates promising activity in models of SCLC

Tiziana Life Sciences reports positive phase IIa data for milciclib in HCC

First patient dosed in phase I study of RBN-2397

Discovery of a selective OX1 receptor antagonist for substance abuse and dependency

Ideaya Biosciences patents AhR modulators

Medshine Discovery presents new ATR kinase inhibitors

Beijing Scitech-Mq Pharmaceuticals divulges VEGFR2 and MET inhibitors

Chinese researchers describe BRD4 inhibitors

New CDK7 inhibitors presented by Ancureall Biomedical Technology (Shanghai)

Optimized liver-directed gene therapy for Pompe's disease evaluated in vivo

Idera Pharmaceuticals and Abbvie to collaborate on immunooncology trial

First safety data presented from phase II trial of revacept

Tonix begins phase I study of TNX-601 for daytime treatment of PTSD

European Commission approves Stelara for moderate to severely active ulcerative colitis

Applied Therapeutics begins phase III study of AT-1001 for diabetic cardiomyopathy

CellCentric initiates phase I/IIa study of CCS-1477 in hematological malignancies

Gilead Sciences initiates phase Ib/II study of GS-4224 in advanced solid tumors

New trials evaluate IPI-549 in combination therapies for solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...